NEXIMMUNE
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology provides an important advance in the development of immunotherapies for a variety of cancers and other diseases. The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cell (APC) population. Natural APCs are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APCs can be damaged, absent or inactive.
NEXIMMUNE
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2011-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.neximmune.com
Total Employee:
11+
Status:
Active
Contact:
3018610009
Email Addresses:
[email protected]
Total Funding:
210.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Irving Investors
Irving Investors investment in Convertible Note - NexImmune
Barer & Son Capital
Barer & Son Capital investment in Series A - NexImmune
Piedmont Capital Partners
Piedmont Capital Partners investment in Series A - NexImmune
ArrowMark Partners
ArrowMark Partners investment in Series A - NexImmune
Amgen Ventures
Amgen Ventures investment in Venture Round - NexImmune
New Enterprise Associates
New Enterprise Associates investment in Venture Round - NexImmune
Pfizer Venture Investments
Pfizer Venture Investments investment in Venture Round - NexImmune
Key Employee Changes
Official Site Inspections
http://www.neximmune.com Semrush global rank: 4.52 M Semrush visits lastest month: 2.36 K
- Host name: 209.182.196.106
- IP address: 209.182.196.106
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "NexImmune"
Home - Neximmune
NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology that uses natural biology to orchestrate a targeted cell …See details»
Our Company - Neximmune
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology.See details»
Leadership - Neximmune
NexImmune, Inc. - LinkedIn
NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation …See details»
NexImmune - Crunchbase Company Profile & Funding
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology provides an important advance in the …See details»
NexImmune - Org Chart, Teams, Culture & Jobs | The Org
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIMâ„¢ technology. View NexImmune's up-to-date …See details»
Neximmune Inc (NEXI) Profile - The Globe and Mail
Nov 24, 2022 · NexImmune Inc. is a clinical-stage biotechnology company. It engages in developing a novel approach to immunotherapy designed to employ the body's own T cells to …See details»
NexImmune Announces Formation of Autoimmune and Infectious …
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to …See details»
NexImmune Reports Fourth Quarter and Full Year 2021 Financial …
Mar 9, 2022 · NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, …See details»
NexImmune Reports Fourth Quarter and Full Year 2022 Financial …
Mar 28, 2023 · NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, …See details»
Contact - Neximmune
NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology platform with broad application across multiple disease …See details»
NexImmune Announces Formation of Autoimmune and Infectious
Jan 5, 2022 · NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, …See details»
NexImmune Announces Presentation of Phase 1/2 Clinical Data at …
Apr 26, 2023 · NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, …See details»
5 Questions With John Trainer, CFO, NexImmune, Inc.
What can you tell us about your current role and company? I’m currently the CFO at NexImmune. We’re in the clinic with a technology from Johns Hopkins that is uniquely good at directing cell …See details»
Our Technology - Neximmune
NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology platform with broad application across multiple disease …See details»
NexImmune Announces Publication in Frontiers in Medicine …
GAITHERSBURG, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to …See details»
Nextmune: Global #1 in allergy and dermatolgy for companion …
Access your patients personalized interactive food list. We continuously organize seminars, webinars and other educational activities for veterinary practitioners. Register for upcoming …See details»
Nextmune: Your global partner in pet specialty pharma
Nextmune is a science-driven, global specialty pharmaceutical company dedicated to better health for dogs, cats and horses.See details»
Our Pipeline - Neximmune
NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology platform with broad application across multiple disease …See details»
Newsroom - Neximmune
Oct 24, 2023 · NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology platform with broad application …See details»